Think of chronic inflammation like a fire that won't go out, which eventually damages the heart. Instead of just trying to put out the fire with chemicals that weaken the whole body, this work finds the body's own 'off-switch' for that inflammation. It uses a person's unique fat profiles to create a custom map for staying healthy.
Current CVD prevention often fails because chronic inflammation is a residual risk that cannot be stopped without suppressing the entire immune system. There is a lack of personalized tools to trigger the body's own inflammation resolution.
A lipidomic profiling methodology, an AI-empowered CARE-IN-HEALTH ATLAS, a digital multi-criteria decision support system (MCDSS), and a point-of-care biosensor.
If you are a diagnostic company dealing with the need for rapid cardiovascular risk screening — this project developed a point-of-care biosensor that monitors the resolution of inflammation. This allows for immediate, personalized health monitoring outside of a central lab.
If you are a software developer dealing with imprecise CVD prevention guidelines — this project developed a multi-criteria decision support system (MCDSS). It guides healthcare professionals to design personalized prevention strategies based on an AI-empowered atlas.
If you are a nutrition firm dealing with generic dietary advice for heart health — this project developed a way to determine the impact of dietary lipid interventions on inflammation. This enables the creation of personalized blueprints for dietary lipids to prevent CVD.
Based on available project data, no specific pricing or cost information for the biosensor is provided.
The project is currently developing methodologies and conducting proof-of-concept clinical trials, meaning it is not yet at industrial scale.
The project data states that the ATLAS will be provided as openly accessible for the scientific community and health care professionals.
The project period runs from 2023-01-01 to 2027-12-31, with the first 18 months focused on methodology and data collection.
Integration is planned through a digital multi-criteria decision support system (MCDSS) designed to guide healthcare professionals in real-life settings.
The consortium is well-balanced for translation, consisting of 11 partners across 6 countries. With a 27% industry ratio (3 industrial partners, including 2 SMEs), there is a clear intent to move from the 7 academic/research entities toward commercial application. The presence of SMEs suggests a focus on agile development of the biosensor and digital tools.
Contact the Institut National de la Santé et de la Recherche Médicale (INSERM) in France.
Contact us to explore licensing opportunities for the lipidomic profiling methods.
